A detailed history of Vanguard Group Inc transactions in Kodiak Sciences Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,655,439 shares of KOD stock, worth $6.51 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,655,439
Previous 1,654,448 0.06%
Holding current value
$6.51 Million
Previous $8.7 Million 55.3%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$2.29 - $4.48 $2,269 - $4,439
991 Added 0.06%
1,655,439 $3.89 Million
Q1 2024

May 10, 2024

BUY
$3.01 - $7.45 $33,043 - $81,786
10,978 Added 0.67%
1,654,448 $8.7 Million
Q4 2023

Feb 14, 2024

BUY
$1.4 - $3.24 $14,635 - $33,870
10,454 Added 0.64%
1,643,470 $5 Million
Q3 2023

Nov 14, 2023

BUY
$1.8 - $7.49 $6,188 - $25,750
3,438 Added 0.21%
1,633,016 $2.94 Million
Q2 2023

Aug 14, 2023

SELL
$4.3 - $9.48 $138,988 - $306,422
-32,323 Reduced 1.94%
1,629,578 $11.2 Million
Q1 2023

May 15, 2023

BUY
$4.81 - $8.88 $22,823 - $42,135
4,745 Added 0.29%
1,661,901 $10.3 Million
Q4 2022

Feb 10, 2023

BUY
$6.52 - $8.05 $72,195 - $89,137
11,073 Added 0.67%
1,657,156 $11.9 Million
Q3 2022

Nov 14, 2022

BUY
$7.57 - $12.5 $402,156 - $664,062
53,125 Added 3.33%
1,646,083 $12.7 Million
Q2 2022

Aug 12, 2022

SELL
$5.04 - $9.48 $3.86 Million - $7.27 Million
-766,522 Reduced 32.49%
1,592,958 $12.2 Million
Q1 2022

May 13, 2022

SELL
$7.09 - $89.45 $4.33 Million - $54.6 Million
-610,430 Reduced 20.55%
2,359,480 $18.2 Million
Q4 2021

Feb 14, 2022

BUY
$80.85 - $128.49 $1.98 Million - $3.15 Million
24,489 Added 0.83%
2,969,910 $252 Million
Q3 2021

Nov 12, 2021

SELL
$81.97 - $106.94 $3.5 Million - $4.57 Million
-42,740 Reduced 1.43%
2,945,421 $283 Million
Q2 2021

Aug 13, 2021

BUY
$77.2 - $126.54 $231 Million - $378 Million
2,988,161 New
2,988,161 $278 Million

Others Institutions Holding KOD

About Kodiak Sciences Inc.


  • Ticker KOD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,040,200
  • Market Cap $205M
  • Description
  • Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...
More about KOD
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.